Semaglutide, Tirzepatide, Retatrutide, AOD9604, Cagrilintide, and metabolic research compounds.
Retatrutide Phase 3 TRIUMPH-1 explained: 2026 topline data (up to ~28% weight loss), trial design, mechanism, and class comparison. Research use only.
Retatrutide Phase 3 TRIUMPH-1: The 2026 Obesity Data Explained Read More »
Survodutide (BI 456906) research guide: dual GLP-1/glucagon receptor agonism, obesity and MASH research, SYNCHRONIZE Phase 3. Research use only.
Survodutide Research Guide: A Dual GLP-1/Glucagon Receptor Agonist Read More »
Mazdutide (LY3305677/IBI362) research guide: GLP-1/glucagon dual agonism, GLORY-1 and DREAMS trials, China NMPA approval. Research use only.
Mazdutide Research Guide: A Dual GLP-1/Glucagon Oxyntomodulin Analog Read More »
Cagrilintide & CagriSema research guide: amylin analog mechanism, REDEFINE Phase 3, amylin + GLP-1 co-administration. Research use only.
Cagrilintide and CagriSema Research Guide: Amylin Analog and GLP-1 Co-Administration Read More »
A research-grade overview of next-generation GLP-1 peptides: survodutide, mazdutide, cagrilintide, and CagriSema, their multi-receptor mechanisms, trial data, and mixed global regulatory status.
Next-Generation GLP-1 Research Peptides Explained Read More »
A research-grade guide to SLU-PP-332, a small-molecule pan-ERR agonist from the Burris laboratory studied as an exercise mimetic for mitochondrial-biogenesis and fatty-acid-oxidation signaling in preclinical models.
SLU-PP-332 Research Guide: A Pan-ERR Agonist Read More »
A research-grade guide to 5-Amino-1MQ, the small-molecule NNMT inhibitor studied in preclinical metabolic models for its effect on the NAD+ precursor and methyl-donor pools.
5-Amino-1MQ Research Guide: NNMT Inhibition & NAD+ Read More »
A research-grade profile of liraglutide and dulaglutide: two foundational GLP-1 receptor agonists that solved the same short-half-life problem with fatty-acid acylation versus Fc-fusion.
Liraglutide and Dulaglutide Research Guide Read More »
Semaglutide is a 31-residue acylated GLP-1 receptor agonist studied for its effects on glucose regulation, body composition, and cardiovascular outcomes. Its long-chain fatty-acid albumin-binding tether extends plasma half-life to roughly seven days, enabling once-weekly dosing in research and clinical contexts. Trial evidence comes from the SUSTAIN, STEP, PIONEER, and SELECT programs — one of the
Semaglutide Research Guide Read More »
Three single-agonist GLP-1 receptor agonists compared at research register: Liraglutide (Victoza, Saxenda), Semaglutide (Ozempic, Wegovy, Rybelsus), and Dulaglutide (Trulicity), across asymmetric Phase 3 evidence bases.
GLP-1 Agonists: Liraglutide vs Semaglutide vs Dulaglutide Read More »
Mechanism-family reference to GLP-1 metabolic research peptides — Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Cagrilintide, Mazdutide, AOD9604, and beyond — across six receptor-agonism families.
GLP-1 / Metabolic Research Peptides: Complete Pillar Guide Read More »
Compound guide to Tirzepatide as the first dual GIP/GLP-1 receptor agonist, covering modified-GIP backbone pharmacology, biased GLP-1R agonism, and the SURPASS and SURMOUNT trial programs.
Tirzepatide Research Guide: Dual GIP/GLP-1 Mechanism Read More »
Binary head-to-head of Retatrutide (triple GIP/GLP-1/glucagon agonist; research-only) and Tirzepatide (dual GIP/GLP-1 agonist; FDA-approved as Mounjaro and Zepbound) — across an approval-status divide.
Retatrutide vs Tirzepatide: Triple vs Dual Agonist Read More »
Comprehensive research guide to AOD9604, the modified human growth hormone fragment 176-191. CAS 221231-10-3, MW 1815.08 g/mol. Lipolytic mechanism without IGF-1 stimulation, published metabolic data, comparison to full-length hGH and HGH Fragment 176-191, and research protocols.
AOD9604 Research Guide: The hGH Fragment for Metabolic Research Read More »
Comprehensive guide to Retatrutide (LY3437943), the first-in-class GIP/GLP-1/glucagon triple receptor agonist. CAS 2381089-83-2, MW 4471.5 g/mol. Triple agonist mechanism, Phase 2 NEJM data, comparison to Tirzepatide and Semaglutide, and research significance.
Side-by-side comparison of Semaglutide (GLP-1 agonist) and Tirzepatide (dual GIP/GLP-1 agonist) for researchers. Molecular structures, receptor pharmacology, head-to-head SURPASS-2 trial data, and the evolution toward triple-agonist peptides like Retatrutide.
Semaglutide vs Tirzepatide: Mechanism, Research Data & Key Differences Read More »
Same day shipping
Multiple payment options
Real-time order tracking
We’re here to help
Apex Laboratory is a specialized supplier of high-purity chemical reagents and peptides. All products listed are strictly for in-vitro laboratory research and development use only.
support@apexlaboratory.org
Mon – Fri
09:00 – 17:00 EST
